Skip to main content
. 2015 May 26;113(1):46–56. doi: 10.1038/bjc.2015.186

Figure 5.

Figure 5

Trimodality therapy in SK-LMS-1 xenografts. (A) Growth of SK-LMS-1 leiomyosarcoma xenografts in athymic nude mice. Groups were treated with control immunoglobulin G (IgG) 20 mg kg−1 three times per week, DC101 20 mg kg−1 three times per week, RT 8 Gy one time, and/or TH-302 50 mg kg−1 five times per week. (B) Tumour weight. Graphs of endothelial-specific apoptosis (C), microvessel density (D), nuclear HIF-1α expression (E), and VEGF-A expression (F) in SK-LMS-1 tumour groups. Bars represent s.d. *P<0.05 compared with IgG control. **P<0.05 compared with all other groups.